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In that Medicaid-sponsored investigation of administrative claims data, the annual (2005) prevalence of any psychotropic medication for Medicaid-enrolled youth in foster care (aged 0 -17 years) in Texas was 34.7%. Disaggregated by age group, the annual psychotropic medication prevalence was 12.4% (ages 0 -5 years), 55.3% (ages 6 -12 years), and 66.5% (ages 13-17 years).
Aside from this recent as-yet-unpublished monograph, the prevalence of psychotropic medication for US youth in foster care placements has rarely been the subject of quantitative research. Zima et al 2 and McMillen et al 3 analyzed interview data from foster care case files, dosReis et al 4 and Ferguson et al 5 used Medicaid administrative claims data from 1 county, and Zito et al 6 and dosReis et al 7 Several members of the staff of the Texas State Comptroller participated in the identification, extraction, and management of data for the study and reviewed and approved the article. Ms Thomas had full access to all the data in the study and takes responsibility for the integrity of the data; Dr Zito takes full responsibility for the accuracy of the data analysis; and Mr Gardner performed statistical analysis.
of medication treatment among youth in foster care. Relevant findings showed that the foster care psychotropic prevalence for youth peaks at ages 10 to 14 years, is 3.5 to 11.0 times greater than the rate for Medicaidinsured youth who qualify because of low family income, and is higher in white youth than in minority youth. 4, 6 Large-scale studies of concomitant psychotropic medication treatment of youth are very limited, and most reports of this practice are based on record reviews. 8 A survey of medication prescribing from numerous private-practicing psychiatrists who volunteered to report on the youth treatment patterns of outpatients under their care revealed that, in 1997-1999, one half were receiving concomitant psychotropic treatment. 9 This practice seems to be increasing. 8, 10 Thus, there is a need for a large-scale, systematic analysis of the practice of concomitant medication treatment of youth. Previous Medicaid data analyses have assessed concomitant psychotropic drug use for youth with Ն2 drugs with overlapping prescribing time periods. Martin et al 11 used a prescribing time period overlap of 7 days, which underestimates temporal coprescribing. Other Medicaid studies assessed a 1-year period 7, 12 and a 3-month period of multiple medication usage, 7, 13 which overestimate coprescribing. Because Medicaid prescriptions are typically written for a 30-day supply, the 1-month period use herein is viewed as optimal to evaluate concomitant treatment.
Medicaid data on individual youth in foster care from the state of Texas were available on computerized records in 2005. From the fiscal year 2004 data, a random sample of 472 youth aged 0 to 19 years was obtained. This information was analyzed with respect to concomitant use. The month of July 2004 was selected to assess the coprescribing. The usage patterns were analyzed for monotherapy and concomitant use according to medication class, subclass and drug entity (all product forms of a drug), diagnosis, age group, gender, race or ethnicity, and prescriber specialty.
METHODS

Among 32 135
Texas foster care 0-to 19-year-old Medicaid enrollees in the study year (September 2003 to August 2004), 12 189 had a dispensed psychotropic medication, resulting in an annual prevalence of 37.9%. Assessing concomitant use required manual assessment of patient-level computerized claims data occurring in 1 month. Consequently, to create a reasonably sized sample, 500 subjects were randomly selected from among those with any psychotropic medication during the month of July 2004, which was representative of monthly use across the study year. Of these, 472 had usable data representing 7.3% of the 6459 medicated youth. This sample did not include mentally retarded and medically fragile youth who are distinct from the general foster care population. The anonymized administrative claims data from this treatment population were assessed by clinician-reported International Classification of Diseases, Ninth Revision, psychiatric diagnoses; age group (0 -4, 5-9, 10 -14, and 15-19 years); gender; race or ethnicity (white, black, Hispanic, and other race or ethnicity); and prescriber specialty (psychiatry versus primary care). The age groupings were selected following the US census groupings for children and have been used in previous pediatric studies. 6 , and miscellaneous (desmopressin, antiparkinsonian, etc). Psychotropic medications (dependent variable) were reported by class (eg, antidepressant), subclass (eg, SSRI, tricyclic, and other antidepressants) and specific drug entity (eg, fluoxetine). Concomitant use was further characterized in terms of within-class and among-class combinations. Independent variables included concomitant/monotherapy users (reported by frequency of concomitant classes, subclasses, and types of combinations). Prescriber specialty was assessed in relation to drug class. Age group, gender, and race or ethnicity were treated as covariates. The University of Maryland Institutional Review Board designated the study exempt.
RESULTS
Characteristics of the Treatment Sample
Of the 472 Medicaid-enrolled youth in foster care receiving psychotropic medication in July 2004, there was a predominance of boys (54.7%), relatively few whites (38.6%), and proportionately more 10-to 14-year-olds (39.0%; Table 1 ). Several additional measures not shown in the table relate to the demographics of psychotropic use. For example, boys and girls each received an average of 1.9 psychiatric diagnoses. Race/ethnicity psychotropic medication disparities were greater for black than for Hispanic youth (white/ black ratio, 1.52:1.00 and white/Hispanic ratio, 1.08:1.00).
Boys received more different classes of psychotropic medication than girls (2.28 vs 2.06; P Ͻ .04).
Diagnostic Findings
Of the clinician-reported diagnoses within the sample, ADHD comprised 38.8%, depression 35.5%, adjustment/anxiety 33.7%, oppositional defiant disorder/conduct disorder comprised 20.6%, and 17.2% were identified as bipolar disorder. The diagnoses most prominent in the younger foster care population were ADHD and adjustment disorder. Depression was the most common diagnosis in 15-to 19-year-old youth. A small proportion of the youth had developmental delays (n ϭ 18), child abuse (n ϭ 24), and miscellaneous conditions (n ϭ 32 [6.8%]), for example, substance abuse (n ϭ 6) and enuresis (n ϭ 4).
Concomitant Users According to Class and Subclass
In July 2004, 130 (27.5%) of the 472 medicated youth received monotherapy, and the rest received concomitant medications. The average number of medications per child was 2.55 (1202 medications for 472 children).
The number of concomitant medications varied by drug class. Table 2 records that 195 (41.3%) of the 472 youth received Ն3 psychotropic medication classes concomitantly, 75 (15.9%) received Ն4, and 10 (2.1%) received Ն5 classes. Table 2 also presents the degree of monotherapy and concomitant therapy by drug class and drug subclass. The ␣-agonists were more often prescribed concomitantly, followed by ATC-MSs and then antipsychotic agents. For youth with dispensings for 2 concomitant drug classes, ADHD medications were the most common class. For those receiving Ն5 concomitant classes, antipsychotic medications were the most prescribed. Between these extremes, antidepressants predominated. Concomitant medication therapy also varied by age. The mean number of psychotropic medication classes by age group was as follows: 1.43 (ages 0 -4 years), 2.29 (ages 5-9 years), 2.54 (ages 10 -14 years), and 2.28 (ages 15-19 years). The rank order of the most common concomitant psychotropic class combinations was as follows: antipsychotics with ADHD medications (n ϭ 134), antipsychotics with antidepressants (n ϭ 132), antidepressants with ADHD medications (n ϭ 125), ATC-MSs with antipsychotic agents (n ϭ 93), and ATC-MSs with antidepressants (N ϭ 77). The concomitant use of Ն2 drugs within the same class rose with the increasing number of medications dispensed. It increased steadily from 17.0% (25 of 147) in 2 drug combinations, 25.0% (30 of 120) in 3, 23.1% (15 of 65) in 4, and 60.0% (6 of 10) in those with 5 or 6 combinations. Table 3 presents the psychotropic medications dispensed to youth in foster care in July 2004 by drug entity within subclass and among classes. Less than 1% of the antipsychotic agents were of the conventional type. Even in the 0-to 4-year age group, nearly half (12 of 23) had been dispensed an antipsychotic agent (data not shown). Fifty-one percent of the antidepressants were in the SSRI subclass. As Alpha agonists a  1  1  21  14  25  21  33  51  4  40  84  Antipsychotic agents a  18  14  74  50  91  75  58  89  10  100  251  Atypical b  17  94  74  100  90  99  58  100  10 to the drug entities, it is of note that prescriptions for oxcarbazepine and topiramate nearly equaled the number for divalproex. Also, of the SSRI antidepressants dispensed in July 2004, patent-protected sertraline and escitalopram comprised 74.8% of the total, whereas generic fluoxetine comprised only 12.0% of the total. Many youth received concomitant drugs within a drug class that is accounted for in column 3 (drugs are listed below the class or subclass), whereas the total use of a class is presented as a percentage of either unduplicated classes (column 4) or unduplicated individuals (column 5). Overall, 56.8% had been dispensed an antidepressant, 55.9% had an ADHD drug, and 53.2% had an antipsychotic agent. Table 4 presents the psychotropic medication patterns within the 3 leading psychiatric diagnostic groups. The diagnostic group most associated with Ն3 dispensed medication classes was depression followed by ADHD and adjustment/anxiety disorders. Generally, psychotropic treatment by medication class was not specific relative to the diagnosis for youth receiving Ն3 classes concomitantly. The only exception to this lack of specificity was the ADHD drug class that was used to a statistically greater degree in the ADHD diagnostic group (df ϭ 2, 227; P ϭ .01). In particular, antipsychotic class prescribing was similar (76%-84%) across all 3 of the leading diagnostic groups (df ϭ 2, 227; P value not significant). The range of medication class frequency by diagnosis was similar although somewhat broader (71%-85%) for antidepressants. Although 83.6% of the youth with an ADHD diagnosis received an ADHD drug, this class represented only 32.6% (153 of 470) of the medication classes dispensed for ADHD.
Psychotropic Medication Entities Within and Among Classes
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Psychotropic Medications According to Diagnosis
Psychotropic Medication Classes According to Prescriber Specialty
Psychiatrists prescribed 93% of the psychotropic agents prescribed for the youth in foster care. Proportionally, psychiatrists tended to prescribe more antipsychotic agents and lithium, whereas primary care physicians tended to prescribe a relatively greater proportion of anxiolytics and stimulants.
DISCUSSION
The major findings from this randomly selected 1-month (July) 2004 sample of 472 psychotropic drug-medicated, Medicaid-insured, youth in foster care can be summarized along 3 dimensions. First, concomitant use was highly prevalent, with 41.3% the youth receiving Ն3 
TABLE 4 Medication Use in 3 Leading Diagnostic Groups
Class ADHD (N ϭ 183) Adjust/Anxiety (N ϭ 159) Depression (N ϭ 167) 
Comparison of Studies of Psychotropic Medication Prevalence for Youth in Foster Care
It is difficult from the available literature to accurately compare the prevalence of psychotropic medications in Medicaid-treated youth in foster care from different jurisdictions (county and state), different years, and using different age groups. However, the psychotropic medication prevalence from 3 county Medicaid foster care studies ranged from 30% to 43%. 4, 5, 15 The prevalence from state Medicaid foster care findings ranged from 25.8% in year 2000 in a mid-Atlantic state 6 to 34.7% in year 2005 among 0-to 17-year-olds 1 and 37.9% in the annual data (0 -19 years; from September 2003 to August 2004) used to select a 1-month random sample of Ͻ20-year-olds for the present study. Compared with nonfoster care Medicaid enrollees, psychotropic drug treatment in the foster care population now equals or exceeds that of eligible youth in the SSI group 16 and is 3.5-to fourfold more prevalent than in Medicaid-insured youth eligible by low family income. 6
ADHD Treatment
In the present 1-month July analysis of Texas youth in foster care, stimulants represented a small portion of psychotropic drug burden in youth with a diagnosis of ADHD. In relation to the total psychotropic medications prescribed, the stimulant drug proportional use was 20.4% (245 of 1202). In 2 other studies by comparison, the proportion of stimulants within the total psychotropic medication burden was 32.6% 4 and 33.4%. 5
Antipsychotic Medication Treatment
Antipsychotic medication as a percentage of total psychotropic medication dispensed to Texas Medicaid-insured foster children was 22.0% (265 of 1202; Table 3 ). In 2 available comparison studies, the antipsychotic proportion of total psychotropic use was 4.5% 2 and 10.3%. 4 This in part reflects the prominent increase in antipsychotic medication given to youth in Texas 17 and elsewhere 18 since the late 1990s. It should also be noted that the use of antipsychotic medication did not vary much across the 3 major diagnostic groups (19.8%, 21.8%, and 21.7% for depression, adjustment/anxiety, and ADHD, respectively). These diagnostic groups are subsets with different denominators than that of the total antipsychotic users (251/147 ϭ 53.2%).
Concomitant Psychotropic Medication Treatment
The use of concomitant psychotropic medication treatment for youth in foster care in this data set is sizably higher than that reported in other studies. 
Use of >2 Drugs Within Class Concomitantly
The use of Ն2 drugs within the same class of psychotropic medication concomitantly has increased of late partly in an effort to improve treatment response. 8 In the present analysis, the occurrence of this pattern ranged from 17% for those receiving 2 psychotropic drug combinations to 60% receiving Ն5 concomitant psychotropic drug classes. Stahl 21 emphasizes that when 2 antipsychotic agents are prescribed concomitantly, there are concerns about the increased risk of adverse events and the lack of an evidence base, as well as substantially increased expenditures. Unnecessary expenditures in the public sector are particularly critical in this era of diminished funding for state programs. 22
Off-label Psychotropic Medications for Youth
All of the atypical antipsychotic medications were offlabel (without Food and Drug Administration-approved labeling for an indication, a dose, or an age group) for youth in 2004, and all of the anticonvulsant drugs were off-label for psychiatric indications in youth. 23 Furthermore, only fluoxetine has Food and Drug Administration-approved labeling for the treatment of depression in youth, although its use in Texas foster children was infrequent in 2004. Although it is true that most drugs in pediatrics are off-label, it is still noteworthy that the ADHD medications with labeled indications for youth, such as stimulants, were used sparingly.
Limitations
Several limitations should be considered in assessing these data. The extent to which these patterns generalize to other state Medicaid foster care medication patterns is not possible to deduce precisely. Medicaid Analytic Extract data files are available from the Centers for Medicare and Medicaid and would allow cross-state comparisons. Consequently, additional national data reflecting youth in foster care should be analyzed. Second, data on dispensed prescriptions do not reflect the extent of consumption. However, the patterns described largely represent chronic therapy, and such continuing treatment generally reflects adherence with drug therapy.
Assessing Quality Improvement Programs
The major concern with among-and within-class concomitant use of psychotropic medications is the increased risk of adverse drug events, including drug interactions. 24, 25 Related concerns are escalating costs, therapeutic duplication, and confusion concerning which drug accounted for what treatment goal. 26 Guidelines listing inappropriate patterns of psychotropic medications prescribed for youth are few. The Texas Department of State Health Services panel, 27 composed of 6 child and adolescent psychiatrists, a research pharmacist, a child psychologist, a physician mental health administrator, and an adult psychiatrist, recently wrote practice guidelines for youth in foster care. They concluded that a department review should be required if antipsychotic agents and antidepressants were prescribed for youth under age 4 years, stimulants under age 3 years, if Ն2 drugs from the same class were prescribed concomitantly, and if Ն5 different classes of psychotropic medication were prescribed concomitantly.
More broadly, statewide Medicaid prescription class data can be useful to identify outliers, thereby suggesting the need for a psychotropic use review. Automated preset clinical guidelines have been used for several decades with the aim of monitoring drug use to assess and improve "quality." 28 Sometimes the emphasis has been on cost containment, which occasionally results in negative consequences. 29 More recently, pharmaceutical industry-funded programs, such as Comprehensive NeuroScience, Inc, 30 have established consensus guidelines that recommend a review if Ն3 concomitant drugs are prescribed for psychiatric use in children. A Massachusetts-initiated multidisciplinary expert panel flags the use of Ն5 concomitant psychotropic agents in adults. 31 The Arizona Department of Health Services 32 clinical practice protocol for psychotropic medication use in children, adolescents, and young adults requires justification if Ͼ2 within-class medications are prescribed and if Ͼ3 from different classes are prescribed concomitantly.
A "5-or-more" concomitant rule for adults is used frequently to monitor quality, although it is not evidence based. From a safety standpoint, taking Ն5 medications concomitantly has been commonly defined in the literature as polypharmacy. This level of use is generally perceived as a cause for concern, although the precise number of comedications to merit this label is not based on scientific findings. 33 When 5 drug combinations in adults or 3 drug combinations in youth are being monitored with Comprehensive NeuroScience, Inc, criteria, the patient record is flagged, and the prescribing physician is notified by mail. Numerous state Medicaid programs have adopted the Comprehensive NeuroScience, Inc, criteria, 30 although each state's program administrators are free to tailor the criteria as they see fit. We were unable to locate studies verifying the outcomes or benefit-risk assessment for 3, 4, or 5 drug psychotropic regimens in a youth population. Although 3 is more reasonable than 5, determining the origin and validity of such rules for concomitant psychotropic use should go beyond expert opinion to evaluate outcomes in large cohorts of youth with well-defined conditions. Population-based clinical monitoring of concomitant regimens may be considered a nuisance by practitioners and needs to be refined so that individual case assessments of appropriateness and value will promote positive outcomes. However, the risks are substantial, because concomitant drug treatments are increasing in the absence of an evidence base.
CONCLUSIONS
Studies reveal that youth in foster care, as a group, have substantially more psychiatric disorders than their peers and that most disorders are behavioral in type. 34, 35 However, it is unclear whether the dispensing of Ն3 different psychotropic medication classes concomitantly to children in foster care represents a treatment advantage. Consequently, benefit/risk research assessments seem to be important for informing practitioners about the best treatment practices.
